Filter Results:
(481)
Show Results For
- All HBS Web
(481)
- People (1)
- News (131)
- Research (322)
- Multimedia (4)
- Faculty Publications (176)
Show Results For
- All HBS Web
(481)
- People (1)
- News (131)
- Research (322)
- Multimedia (4)
- Faculty Publications (176)
- December 2006 (Revised August 2008)
- Case
Pervasis Therapeutics, Inc.
By: Robert F. Higgins and Virginia Fuller
In May 2005, Steve Bollinger was about to become president and chief operating officer of Pervasis Therapeutics, a small cell therapy start-up in Cambridge, Mass. If proven successful, Pervasis' product, Vascugel, could change the way vascular disease is treated and... View Details
Keywords: Business Startups; Venture Capital; Financial Strategy; Governing Rules, Regulations, and Reforms; Health Care and Treatment; Health Testing and Trials; Health Industry; Cambridge
Higgins, Robert F., and Virginia Fuller. "Pervasis Therapeutics, Inc." Harvard Business School Case 807-026, December 2006. (Revised August 2008.)
- 28 Jun 2011
- News
Beyond Case Writing
interest in global health to the realization that an estimated 13 million people die each year for lack of low-cost products that could save their lives. Over the past seven years, she has conducted research projects in Zambia aimed at... View Details
- Web
Employers - Institute For Strategy And Competitiveness
currently part of the employer’s health plan Support insurance reform that levels the playing field among employers Health benefits must ultimately be a senior management... View Details
- 01 Sep 2010
- News
RX for Change
employs 9,000 people and ranks as Georgia’s largest, most comprehensive health system. Under consideration this day is a proposal to add specialists — known as neurohospitalists — to manage care for patients with disorders such as stroke.... View Details
- Profile
Inessa Lurye
MBA/MPP degree at HBS and Harvard Kennedy School, Inessa helped expand the reach of the HBS Design Club, and fulfilled a field project at Harvard Art Museums that developed art workshops designed around specific group interests. One thing her work never touched upon... View Details
- 29 Jan 2015
- Op-Ed
The Fall of Greece
Professor of Business Administration and a native of Greece, offers his insights into what the election means for the country. Many people ask me what the recent elections in Greece mean for the Greek economy. While I agree reforms are... View Details
Keywords: by George Serafeim
- 26 Apr 2016
- First Look
April 26
the infant private sector in urban China. We show that a reform that untied access to housing in urban areas from working for the state sector accounts for more than a quarter of the overall increase in labor supply to the private sector... View Details
Keywords: Sean Silverthorne
- 10 Jan 2005
- What Do You Think?
Public Pension Reform: Does Mexico Have the Answer?
Summing Up Judging from responses to the January column, the debate concerning reform of the social security system in the U.S. will take many directions before the question can even be framed adequately. If the responses are an... View Details
- 23 Jul 2013
- First Look
First Look: July 23
School Case 713-483 Yammer (B) Supplement to "Yammer (A)," HBS case 713-407 Purchase this case: http://hbr.org/search/713483-PDF-ENG Harvard Business School Case 712-466 Moving to Universal Coverage: Health Care View Details
Keywords: Anna Secino
- April 2011 (Revised October 2011)
- Teaching Note
U.S. Healthcare Reform: International Perspectives (TN)
By: Arthur A. Daemmrich and Elia Cameron
Teaching Note for #710-040 and 711-103. View Details
- fall 2007
- Article
Pharmaceutical Regulation in the United States and Europe
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Pharmaceutical Regulation in the United States and Europe." Focus on Law Studies 23, no. 1 (fall 2007): 8–11.
- 10 Aug 2011
- Research & Ideas
HBS Faculty Views on Debt Crisis
of perhaps $90 trillion. One side argues that we can't raise revenues, while the other asserts we can't cut entitlements. Both sides are wrong. Entitlement costs, especially health care, will eat us alive. Without real View Details
Keywords: by Staff
- Web
What Others Are Saying - Institute For Strategy And Competitiveness
Health Care “Redefining Health Care has caught the imagination of many of the most influential voices in NHS reform and has been occupying minds at the highest level throughout... View Details
- 01 Sep 2010
- News
Noted & Quoted
also be a statutory cap on leverage, a maximum speed limit, if you will, that regulators can’t loosen.” — HBS professor David Moss commenting on the need for financial reform legislation to place limits on the amount banks can borrow for... View Details
- October 2024
- Article
Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates
By: Pragya Kakani, Michael Anne Kyle, Amitabh Chandra and Luca Maini
Medicare Part D does not allow plans to exclude drugs in six protected classes from their formularies, which may limit plans’ ability to negotiate rebates and lead to higher spending. We estimated the association between protected-class status, US-level estimated... View Details
Keywords: Insurance; Health Care and Treatment; Governing Rules, Regulations, and Reforms; United States
Kakani, Pragya, Michael Anne Kyle, Amitabh Chandra, and Luca Maini. "Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates." Health Affairs 43, no. 10 (October 2024): 1420–1427.
- June 9, 2023
- Article
A Radical Treatment for Insulin Pricing
By: Leemore S. Dafny
In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a... View Details
Keywords: Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States
Dafny, Leemore S. "A Radical Treatment for Insulin Pricing." New England Journal of Medicine 386, no. 23 (June 9, 2023): 2157–2159.
- Article
Use of Connected Digital Products in Clinical Research Following the COVID-19 Pandemic: A Comprehensive Analysis of Clinical Trials
By: Caroline Marra, William J. Gordon and Ariel Dora Stern
Objectives: In an effort to mitigate COVID-19 related challenges for clinical research, the U.S. Food and Drug Administration (FDA) issued new guidance for the conduct of ‘virtual’ clinical trials in late March 2020. This study documents trends in the use of... View Details
Keywords: Connected Digital Products; Telehealth; Remote Monitoring; Health Testing and Trials; Research; Governing Rules, Regulations, and Reforms; Information Technology
Marra, Caroline, William J. Gordon, and Ariel Dora Stern. "Use of Connected Digital Products in Clinical Research Following the COVID-19 Pandemic: A Comprehensive Analysis of Clinical Trials." BMJ Open 11, no. 6 (2021).
- 2024
- Working Paper
Fecal Microbiota Transplants —Too Simple to be Safe? Case Histories of Transformational Advances
By: Amar Bhide and Srikant M. Datar
By 2013, after many decades of very slow development and adoption, Fecal Microbiota Transplantation procedures were attracting widespread attention. This case history chronicles the: 1) pioneering fecal transplants performed in the 20th century; 2) development of the... View Details
Keywords: Health Care and Treatment; Innovation and Invention; Governing Rules, Regulations, and Reforms
Bhide, Amar, and Srikant M. Datar. "Fecal Microbiota Transplants —Too Simple to be Safe? Case Histories of Transformational Advances." Harvard Business School Working Paper, No. 21-132, June 2021. (Revised May 2024.)
- 01 Sep 2012
- News
A Silent Workplace Crisis
pharmaceuticals, the gap between the medical and the mental health systems, and the time required to find community resources and quality home care. My previous experience as a pharmaceutical executive and management consultant seemed... View Details
- 26 Jul 2016
- Working Paper Summaries